Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BGNE Stock Summary
Top 10 Correlated ETFs
BGNE
In the News
BGNE Financial details
Company Rating
Neutral
Market Cap
15.53B
Income
-881.71M
Revenue
2.46B
Book val./share
33.99
Cash/share
30.61
Dividend
-
Dividend %
-
Employees
10.6K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-17.71
Forward P/E
-
PEG
3.13
P/S
6.81
P/B
4.41
P/C
4.32
P/FCF
-9.54
Quick Ratio
1.98
Current Ratio
2.32
Debt / Equity
0.26
LT Debt / Equity
0.06
-
-
EPS (TTM)
-8.45
EPS next Y
-
EPS next Q
-
EPS this Y
-56.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.8%
Revenue last 5Y
41.84%
Revenue Q/Q
-18.8%
EPS Q/Q
-271.36%
-
-
-
-
SMA20
-15.48%
SMA50
-6.58%
SMA100
-25.26%
Inst Own
41.97%
Inst Trans
0.93%
ROA
-15%
ROE
-23%
ROC
-0.3%
Gross Margin
66%
Oper. Margin
-49%
Profit Margin
-36%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
132.95-270.57
52W High
-51.06%
52W Low
+0.1%
RSI
30
Rel Volume
0.6
Avg Volume
261.91K
Volume
156.98K
Perf Week
-14.21%
Perf Month
-17.17%
Perf Quarter
-20.63%
Perf Half Y
-24.04%
-
-
-
-
Beta
0.627
-
-
Volatility
6.18%, 11.33%
Prev Close
-1.43%
Price
132.13
Change
-5.74%
BGNE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 7.13 | 3.7 | 12.68 | 13.73 | 23.55 | |
Net income per share | -15.83 | -19.17 | -15.23 | -19.43 | -8.45 | |
Operating cash flow per share | -12.49 | -15.38 | -14 | -14.51 | -11.09 | |
Free cash flow per share | -15.13 | -18.12 | -17.39 | -19.06 | -16.66 | |
Cash per share | 16.36 | 55.72 | 71.32 | 43.97 | 30.52 | |
Book value per share | 16.29 | 46.35 | 67.28 | 42.5 | 33.89 | |
Tangible book value per share | 15.41 | 45.71 | 66.17 | 41.58 | 33.17 | |
Share holders equity per share | 16.29 | 46.35 | 67.28 | 42.5 | 33.89 | |
Interest debt per share | 4.77 | 6.74 | 7.32 | 9.15 | 9.06 | |
Market cap | 9.95B | 21.57B | 25.14B | 22.68B | 18.83B | |
Enterprise value | 9.61B | 20.75B | 21.46B | 19.7B | 16.57B | |
P/E ratio | -10.47 | -13.48 | -17.79 | -11.32 | -21.35 | |
Price to sales ratio | 23.25 | 69.83 | 21.37 | 16.02 | 7.66 | |
POCF ratio | -13.27 | -16.8 | -19.36 | -15.16 | -16.27 | |
PFCF ratio | -10.95 | -14.26 | -15.58 | -11.54 | -10.83 | |
P/B Ratio | 10.17 | 5.57 | 4.03 | 5.17 | 5.32 | |
PTB ratio | 10.17 | 5.57 | 4.03 | 5.17 | 5.32 | |
EV to sales | 22.45 | 67.17 | 18.24 | 13.92 | 6.74 | |
Enterprise value over EBITDA | -10.03 | -12.52 | -14.92 | -11.01 | -14.8 | |
EV to operating cash flow | -12.81 | -16.17 | -16.52 | -13.17 | -14.32 | |
EV to free cash flow | -10.58 | -13.72 | -13.3 | -10.02 | -9.53 | |
Earnings yield | -0.1 | -0.07 | -0.06 | -0.09 | -0.05 | |
Free cash flow yield | -0.09 | -0.07 | -0.06 | -0.09 | -0.09 | |
Debt to equity | 0.28 | 0.15 | 0.11 | 0.2 | 0.26 | |
Debt to assets | 0.17 | 0.1 | 0.08 | 0.14 | 0.16 | |
Net debt to EBITDA | 0.36 | 0.49 | 2.56 | 1.66 | 2.01 | |
Current ratio | 4.1 | 4.61 | 4.76 | 4.63 | 2.32 | |
Interest coverage | -105.12 | -4.9K | 91.31 | -34.1 | -32.32 | |
Income quality | 0.79 | 0.8 | 0.92 | 0.75 | 1.31 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.17 | 4.19 | 1.24 | 1.16 | 0.69 | |
Intangibles to total assets | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | |
Capex to operating cash flow | 0.21 | 0.18 | 0.24 | 0.31 | 0.5 | |
Capex to revenue | -0.37 | -0.74 | -0.27 | -0.33 | -0.24 | |
Capex to depreciation | -8.52 | -7.2 | -6.78 | -7.08 | -6.63 | |
Stock based compensation to revenue | 0.31 | 0.59 | 0.2 | 0.21 | 0.15 | |
Graham number | 76.17 | 141.42 | 151.86 | 136.31 | 80.25 | |
ROIC | -0.75 | -0.37 | -0.2 | -0.34 | -0.29 | |
Return on tangible assets | -0.61 | -0.29 | -0.17 | -0.32 | -0.15 | |
Graham Net | 6.96 | 36.22 | 50.77 | 27.25 | 13.96 | |
Working capital | 886.65M | 3.89B | 6.01B | 3.7B | 2.39B | |
Tangible asset value | 925.44M | 3.82B | 6.14B | 4.29B | 3.46B | |
Net current asset value | 538.76M | 3.23B | 5.21B | 2.72B | 1.97B | |
Invested capital | 0.28 | 0.15 | 0.11 | 0.2 | 0.26 | |
Average receivables | 62.79M | 76.24M | 289.92M | 336.67M | 284.53M | |
Average payables | 117.89M | 177.22M | 247.18M | 278.59M | 304.95M | |
Average inventory | 22.4M | 58.92M | 165.96M | 262.49M | 349.23M | |
Days sales outstanding | 62.06 | 94.15 | 155.2 | 44.64 | 58.77 | |
Days payables outstanding | 44.77 | 62 | 58.97 | 55.84 | 247.96 | |
Days of inventory on hand | 10.44 | 23.87 | 54.53 | 53.48 | 327.44 | |
Receivables turnover | 5.88 | 3.88 | 2.35 | 8.18 | 6.21 | |
Payables turnover | 8.15 | 5.89 | 6.19 | 6.54 | 1.47 | |
Inventory turnover | 34.97 | 15.29 | 6.69 | 6.82 | 1.11 | |
ROE | -0.97 | -0.41 | -0.23 | -0.46 | -0.25 | |
Capex per share | -2.64 | -2.74 | -3.39 | -4.55 | -5.57 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.66 | 4.3 | 5.69 | 7.46 | 6.1 | |
Net income per share | -4.29 | -3.34 | -3.64 | 2.06 | -3.53 | |
Operating cash flow per share | -3.07 | -5.41 | -2.81 | -0.75 | -2.13 | |
Free cash flow per share | -4.71 | -6.62 | -3.97 | -2.49 | -3.73 | |
Cash per share | 43.7 | 36.79 | 33.6 | 30.33 | 30.61 | |
Book value per share | 42.24 | 39.91 | 36.3 | 35.95 | 33.99 | |
Tangible book value per share | 41.33 | 39.53 | 35.85 | 35.44 | 33.27 | |
Share holders equity per share | 42.24 | 39.91 | 36.3 | 35.95 | 33.99 | |
Interest debt per share | 8.76 | 4.9 | 6.53 | 5.71 | 8.81 | |
Market cap | 22.82B | 22.45B | 18.66B | 18.83B | 18.77B | |
Enterprise value | 19.84B | 19.46B | 15.92B | 16.34B | 16.52B | |
P/E ratio | -12.81 | -16.11 | -12.24 | 21.85 | -12.77 | |
Price to sales ratio | 60.04 | 50.14 | 31.34 | 24.1 | 29.59 | |
POCF ratio | -71.72 | -39.82 | -63.48 | -240.91 | -84.69 | |
PFCF ratio | -46.75 | -32.57 | -44.92 | -72.29 | -48.31 | |
P/B Ratio | 5.21 | 5.4 | 4.91 | 5 | 5.31 | |
PTB ratio | 5.21 | 5.4 | 4.91 | 5 | 5.31 | |
EV to sales | 52.21 | 43.45 | 26.75 | 20.91 | 26.04 | |
Enterprise value over EBITDA | -42.36 | -52.41 | -53.73 | -121.97 | -45.89 | |
EV to operating cash flow | -62.36 | -34.51 | -54.18 | -209.08 | -74.53 | |
EV to free cash flow | -40.64 | -28.23 | -38.34 | -62.74 | -42.51 | |
Earnings yield | -0.02 | -0.02 | -0.02 | 0.01 | -0.02 | |
Free cash flow yield | -0.02 | -0.03 | -0.02 | -0.01 | -0.02 | |
Debt to equity | 0.2 | 0.13 | 0.18 | 0.15 | 0.26 | |
Debt to assets | 0.14 | 0.09 | 0.12 | 0.1 | 0.16 | |
Net debt to EBITDA | 6.36 | 8.06 | 9.22 | 18.57 | 6.26 | |
Current ratio | 4.63 | 3.75 | 3.13 | 3.16 | 2.32 | |
Interest coverage | -25.72 | 10.82 | -59.92 | -7.34 | -43.26 | |
Income quality | 0.71 | 1.62 | 0.77 | -0.36 | 0.6 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 3.32 | 0.91 | 0.71 | 0.58 | 0.75 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
Capex to operating cash flow | 0.53 | 0.22 | 0.41 | 2.33 | 0.75 | |
Capex to revenue | -0.45 | -0.28 | -0.2 | -0.23 | -0.26 | |
Capex to depreciation | -9.44 | -6.28 | -5.44 | -8.47 | -7.01 | |
Stock based compensation to revenue | 0.21 | 0.17 | 0.17 | 0.12 | 0.15 | |
Graham number | 63.87 | 54.81 | 54.55 | 40.8 | 51.97 | |
ROIC | -0.09 | -0.08 | -0.07 | -0.03 | -0.09 | |
Return on tangible assets | -0.07 | -0.06 | -0.07 | 0.04 | -0.06 | |
Graham Net | 27.08 | 23.34 | 19.12 | 17.55 | 14 | |
Working capital | 3.7B | 3.45B | 3B | 2.77B | 2.39B | |
Tangible asset value | 4.29B | 4.12B | 3.75B | 3.71B | 3.46B | |
Net current asset value | 2.72B | 2.9B | 2.47B | 2.29B | 1.97B | |
Invested capital | 0.2 | 0.13 | 0.18 | 0.15 | 0.26 | |
Average receivables | 187.91M | 252.66M | 335.15M | 346.38M | 375.25M | |
Average payables | 273.43M | 268.07M | 254.17M | 304.42M | 328.48M | |
Average inventory | 286.63M | 289.67M | 309.16M | 319.13M | 366.53M | |
Days sales outstanding | 41 | 66.76 | 51.12 | 40.85 | 56.16 | |
Days payables outstanding | 51.06 | 265.59 | 46.32 | 319.46 | 220.65 | |
Days of inventory on hand | 48.91 | 326.81 | 55.75 | 296.17 | 291.37 | |
Receivables turnover | 2.19 | 1.35 | 1.76 | 2.2 | 1.6 | |
Payables turnover | 1.76 | 0.34 | 1.94 | 0.28 | 0.41 | |
Inventory turnover | 1.84 | 0.28 | 1.61 | 0.3 | 0.31 | |
ROE | -0.1 | -0.08 | -0.1 | 0.06 | -0.1 | |
Capex per share | -1.64 | -1.21 | -1.16 | -1.74 | -1.6 |
BGNE Frequently Asked Questions
What is BeiGene, Ltd. stock symbol ?
BeiGene, Ltd. is a US stock , located in Cambridge of Ma and trading under the symbol BGNE
What is BeiGene, Ltd. stock quote today ?
BeiGene, Ltd. stock price is $132.13 today.
Is BeiGene, Ltd. stock public?
Yes, BeiGene, Ltd. is a publicly traded company.